115 related articles for article (PubMed ID: 21392921)
1. Investigational study of tamoxifen phase I metabolites using chromatographic and spectroscopic analytical techniques.
Teunissen SF; Rosing H; Seoane MD; Brunsveld L; Schellens JH; Schinkel AH; Beijnen JH
J Pharm Biomed Anal; 2011 Jun; 55(3):518-26. PubMed ID: 21392921
[TBL] [Abstract][Full Text] [Related]
2. An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4'-hydroxylated metabolites in breast cancer patients.
Dahmane E; Mercier T; Zanolari B; Cruchon S; Guignard N; Buclin T; Leyvraz S; Zaman K; Csajka C; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Dec; 878(32):3402-14. PubMed ID: 21094101
[TBL] [Abstract][Full Text] [Related]
3. Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients.
Poon GK; Chui YC; McCague R; Lłnning PE; Feng R; Rowlands MG; Jarman M
Drug Metab Dispos; 1993; 21(6):1119-24. PubMed ID: 7905393
[TBL] [Abstract][Full Text] [Related]
4. Bioanalytical methods for determination of tamoxifen and its phase I metabolites: a review.
Teunissen SF; Rosing H; Schinkel AH; Schellens JH; Beijnen JH
Anal Chim Acta; 2010 Dec; 683(1):21-37. PubMed ID: 21094378
[TBL] [Abstract][Full Text] [Related]
5. An UPLC-MS/MS method for separation and accurate quantification of tamoxifen and its metabolites isomers.
Arellano C; Allal B; Goubaa A; Roché H; Chatelut E
J Pharm Biomed Anal; 2014 Nov; 100():254-261. PubMed ID: 25173109
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a quantitative assay for the determination of tamoxifen and its five main phase I metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry.
Teunissen SF; Jager NG; Rosing H; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jun; 879(19):1677-85. PubMed ID: 21543272
[TBL] [Abstract][Full Text] [Related]
7. Ultra-high performance liquid chromatography tandem mass spectrometric method for the determination of tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in dried blood spots--development, validation and clinical application during breast cancer adjuvant therapy.
Antunes MV; Raymundo S; de Oliveira V; Staudt DE; Gössling G; Peteffi GP; Biazús JV; Cavalheiro JA; Tre-Hardy M; Capron A; Haufroid V; Wallemacq P; Schwartsmann G; Linden R
Talanta; 2015 Jan; 132():775-84. PubMed ID: 25476377
[TBL] [Abstract][Full Text] [Related]
8. A prospective case series of women with estrogen receptor-positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen.
Balkenende EM; Dahhan T; Linn SC; Jager NG; Beijnen JH; Goddijn M
Hum Reprod; 2013 Apr; 28(4):953-9. PubMed ID: 23335608
[TBL] [Abstract][Full Text] [Related]
9. Development of a methodology to quantify tamoxifen and endoxifen in breast cancer patients by micellar liquid chromatography and validation according to the ICH guidelines.
Aranda EO; Esteve-Romero J; Rambla-Alegre M; Peris-Vicente J; Bose D
Talanta; 2011 Apr; 84(2):314-8. PubMed ID: 21376950
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry.
Teunissen SF; Rosing H; Koornstra RH; Linn SC; Schellens JH; Schinkel AH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Aug; 877(24):2519-29. PubMed ID: 19589736
[TBL] [Abstract][Full Text] [Related]
11. Biomonitoring of urinary tamoxifen and its metabolites from breast cancer patients using nonaqueous capillary electrophoresis with electrospray mass spectrometry.
Carter SJ; Li XF; Mackey JR; Modi S; Hanson J; Dovichi NJ
Electrophoresis; 2001 Aug; 22(13):2730-6. PubMed ID: 11545399
[TBL] [Abstract][Full Text] [Related]
12. Optimizing high-performance liquid chromatography method with fluorescence detection for quantification of tamoxifen and two metabolites in human plasma: application to a clinical study.
Zhu YB; Zhang Q; Zou JJ; Yu CX; Xiao DW
J Pharm Biomed Anal; 2008 Jan; 46(2):349-55. PubMed ID: 18037598
[TBL] [Abstract][Full Text] [Related]
13. Study of tamoxifen urinary metabolites in rat by ultra-high-performance liquid chromatography time-of-flight mass spectrometry.
Domínguez-Romero JC; García-Reyes JF; Beneito-Cambra M; Martínez-Romero R; Martinez-Lara E; Del Moral-Leal ML; Molina-Díaz A
Biomed Chromatogr; 2015 Aug; 29(8):1220-8. PubMed ID: 25611330
[TBL] [Abstract][Full Text] [Related]
14. Highly sensitive simultaneous quantification of estrogenic tamoxifen metabolites and steroid hormones by LC-MS/MS.
Johänning J; Heinkele G; Precht JC; Brauch H; Eichelbaum M; Schwab M; Schroth W; Mürdter TE
Anal Bioanal Chem; 2015 Sep; 407(24):7497-502. PubMed ID: 26206706
[TBL] [Abstract][Full Text] [Related]
15. Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours.
MacCallum J; Cummings J; Dixon JM; Miller WR
Br J Cancer; 2000 May; 82(10):1629-35. PubMed ID: 10817496
[TBL] [Abstract][Full Text] [Related]
16. Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile.
Lien EA; Solheim E; Kvinnsland S; Ueland PM
Cancer Res; 1988 Apr; 48(8):2304-8. PubMed ID: 3349495
[TBL] [Abstract][Full Text] [Related]
17. Serum and urine levels of tamoxifen and its metabolites in patients with advanced breast cancer after a loading dose and at steady-state levels.
de Vos D; Slee PH; Briggs RJ; Stevenson D
Cancer Chemother Pharmacol; 1998; 42(6):512-4. PubMed ID: 9788580
[TBL] [Abstract][Full Text] [Related]
18. Sensitive HPLC-PDA determination of tamoxifen and its metabolites N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in human plasma.
Antunes MV; Rosa DD; Viana Tdos S; Andreolla H; Fontanive TO; Linden R
J Pharm Biomed Anal; 2013 Mar; 76():13-20. PubMed ID: 23291438
[TBL] [Abstract][Full Text] [Related]
19. Identification of drug metabolites in human plasma or serum integrating metabolite prediction, LC-HRMS and untargeted data processing.
Jacobs PL; Ridder L; Ruijken M; Rosing H; Jager NG; Beijnen JH; Bas RR; van Dongen WD
Bioanalysis; 2013 Sep; 5(17):2115-28. PubMed ID: 23962251
[TBL] [Abstract][Full Text] [Related]
20. Structural elucidation of new urinary tamoxifen metabolites by liquid chromatography quadrupole time-of-flight mass spectrometry.
Lu J; He C; He G; Wang X; Xu Y; Wu Y; Dong Y; Ouyang G
J Mass Spectrom; 2014 Jul; 49(7):570-8. PubMed ID: 25044841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
